Bruce Levine, the leading trainer at Monmouth Park, had his entire stable of 41 horses tested for erythropoietin, commonly known as EPO, by a New Jersey state veterinarian who made a surprise visit to Levine's Monmouth barn June 24 at the request of the New Jersey Racing Commission.
Delaware is taking a harder line on use of erythropoietin and similar blood-doping agents.
A Pennsylvania laboratory is the first to employ a definitive test for erythropoietin--the blood-doping agent commonly known as EPO--and the test resulted in the suspension and fining of a trainer of Standardbreds in Ontario, Canada.
Industry officials, during a preliminary meeting Dec. 2 at Philadelphia Park, discussed testing for erythropoietin antibodies that could be implemented in Pennsylvania and perhaps a few other Mid-Atlantic states in 2004.
The racing commissions that govern Thoroughbred and Standardbred racing in Delaware have been testing for erythropoietin antibodies since June 1, and in the future may implement rules to penalize horses that test positive.
Testing of post race samples for erythropoietin and darbepoietin antibodies will begin Nov. 1 in New York under an emergency rule approved Oct. 21 by the state's Racing and Wagering Board.
- By Gary West
By Gary West -- Positive tests detecting the presence of EPO antibodies in horses pose an integrity problem for racing that is far graver than the Breeders' Cup Ultra Pick 6 scam.
The Kentucky Equine Drug Research Council met Thursday at Keeneland to discuss options to identify and enforce the prohibited use of erythropoietin (EPO).
Erythropoietin (EPO), a human medication designed to increase the concentration of red blood cells that is rumored to be in use on racehorses, has been added to the list of prohibited veterinary substances on racing premises by the California Horse Racing Board.
The Pennsylvania State Horse Racing Commission has issued an advisory that erythropoietin, or EPO, and other blood-doping substances and procedures are not permitted in the state.
The Kentucky Racing Commission said June 25 it would consider at its next meeting in September a motion to make the possession or use of erythropoietin, known as EPO, a prohibited practice.
The Los Angeles County Fair's desire to move its September racing meet to Santa Anita Park has become a referendum on Magna Entertainment Corp.'s control of California racing dates.
The New South Wales Racing Laboratory has developed a test to detect the drug erythropoietin, commonly known as EPO, in racehorses, according to release on the Racing New South Wales Web site. The medication is considered a performance-enhancer.
Most Popular Stories
- Leagues Seek to Halt New Jersey Sports Bets
- KY Necropsy Program Disproves 'Bad Step' Myth
- F-T October Sale Gains Across Board at Opener
- Researchers Examine Fatal Lumbar Vertebral Fractures
- Sweet Reason Set for BC Filly and Mare Sprint
- Rockingham Park Selling Most of Stable Area
- Claimer Seeking the Sherif Reaches BC Sprint
- Jockeys' Guild, RTCA Set Up Saez Family Fund
- Two-Time Champion Beholder Out of BC Distaff
- Bullet Move for Likely BC Juvenile Favorite